ArticleMedecine tropicale et sante internationale2024
[Evaluation of snakebite management cost at Saint Jean de Dieu Hospital in Tanguiéta, Benin].
Article in Medecine tropicale et sante internationale, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [Evaluation of the Efficacy and Tolerance of Tranexamic Acid Combined with InoserpMedecine tropicale et sante internationale · 2026Trial
- Epidemiologic, clinical, and therapeutic aspects of formally identified Echis romani bites in northern Cameroon.PLoS neglected tropical diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Snakebite envenomations are a real public health problem in rural areas of sub-Saharan Africa, especially as the cost of management is often beyond the reach of the victims. The aim of our study was to evaluate the costs of treating snakebite envenomations at the Saint Jean de Dieu hospital in Tanguiéta, northern Benin, in a savannah area. Methods: This was a descriptive cross-sectional study conducted over a three-month period from May 25 to August 25, 2023. Snakebite patients were followed from admission to hospital discharge. All care-related expenses incurred by patients and/or their families were accounted for on a daily basis. Results: Fifty-seven patients were included. The median age (interquartile range) of the patients was 27 years (16-40), and the sex ratio was 1.6 (35 males and 22 females). In 81% of cases, the bites were associated with agricultural activities. Approximately 72% of the patients had sought traditional care before coming to the hospital. The median time from bite to admission was 7 hours (2-52) and the median hospital stay was 4 days (2-5). The median cost of care was €168 (154-242). It varied according to the severity of the bite: €31 for a dry bite (26-47); €179 for external bleeding (154-286). The only antivenom used was Inoserp™ PAN-AFRICA (Inosan Biopharma). Its average cost was €128 and was the main expense. Conclusion: The cost of treating snakebite is high and dominated by the cost of antivenom. These economic constraints reinforce the vicious circle of poverty in an already vulnerable population. It is therefore important to find a financing mechanism for this treatment in the most exposed areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.